Development of small bisquaternary cholinesterase inhibitors as drugs for pre-treatment of nerve agent poisonings

Background Intoxication by nerve agents could be prevented by using small acetylcholinesterase inhibitors (eg, pyridostigmine) for potentially exposed personnel. However, the serious side effects of currently used drugs led to research of novel potent molecules for prophylaxis of organophosphorus intoxication. Methods The molecular design, molecular docking, chemical synthesis, in vitro methods (enzyme inhibition, cytotoxicity, and nicotinic receptors modulation), and in vivo methods (acute toxicity and prophylactic effect) were used to study bispyridinium, bisquinolinium, bisisoquinolinium, and pyridinium-quinolinium/isoquinolinium molecules presented in this study. Results The studied molecules showed non-competitive inhibitory ability towards human acetylcholinesterase in vitro that was further confirmed by molecular modelling studies. Several compounds were selected for further studies. First, their cytotoxicity, nicotinic receptors modulation, and acute toxicity (lethal dose for 50% of laboratory animals [LD50]; mice and rats) were tested to evaluate their safety with promising results. Furthermore, their blood levels were measured to select the appropriate time for prophylactic administration. Finally, the protective ratio of selected compounds against soman-induced toxicity was determined when selected compounds were found similarly potent or only slightly better to standard pyridostigmine. Conclusion The presented small bisquaternary molecules did not show overall benefit in prophylaxis of soman-induced in vivo toxicity.

[1]  P. Masson,et al.  Cholinesterase reactivators and bioscavengers for pre‐ and post‐exposure treatments of organophosphorus poisoning , 2017, Journal of neurochemistry.

[2]  J. Korábečný,et al.  The Evaluation of Benefit of Newly Prepared Reversible Inhibitors of Acetylcholinesterase and Commonly Used Pyridostigmine as Pharmacological Pretreatment of Soman-Poisoned Mice. , 2017, Acta medica.

[3]  K. Kuča,et al.  Small Quaternary Inhibitors K298 and K524: Cholinesterases Inhibition, Absorption, Brain Distribution, and Toxicity , 2015, Neurotoxicity Research.

[4]  K. Kuča,et al.  Prophylactic administration of non‐organophosphate cholinesterase inhibitors before acute exposure to organophosphates: assessment using terbufos sulfone , 2014, Journal of applied toxicology : JAT.

[5]  K. Kuča,et al.  The interaction of quaternary reversible acetylcholinesterase inhibitors with the nicotinic receptor. , 2014, Physiological research.

[6]  K. Kuča,et al.  Preparation, in vitro evaluation and molecular modelling of pyridinium-quinolinium/isoquinolinium non-symmetrical bisquaternary cholinesterase inhibitors. , 2013, Bioorganic & medicinal chemistry letters.

[7]  K. Kuča,et al.  Usefulness of administration of non‐organophosphate cholinesterase inhibitors before acute exposure to organophosphates: assessment using paraoxon , 2013, Journal of applied toxicology : JAT.

[8]  K. Kuča,et al.  Pharmacokinetic study of two acetylcholinesterase reactivators, trimedoxime and newly synthesized oxime K027, in rat plasma , 2013, Journal of applied toxicology : JAT.

[9]  K. Kuča,et al.  Pharmacokinetics of acetylcholinesterase reactivator K203 and consequent evaluation of low molecular weight antioxidants/markers of oxidative stress , 2012 .

[10]  K. Musílek,et al.  A comparison of the efficacy of newly developed reversible inhibitors of acetylcholinesterase with commonly used pyridostigmine as pharmacological pre-treatment of soman-poisoned mice. , 2012, Basic & clinical pharmacology & toxicology.

[11]  K. Kuča,et al.  Acetylcholinesterase inhibitors as pretreatment before acute exposure to organophosphates: assessment using methyl-paraoxon. , 2012, CNS & neurological disorders drug targets.

[12]  Zhaohui J. Cai,et al.  Pretreatment data is highly predictive of liver chemistry signals in clinical trials , 2012, Drug design, development and therapy.

[13]  K. Kuča,et al.  OXIMES AS INHIBITORS OF ACETYLHOLINESTERASE - A STRUCTURE-ACTIVITY RELATIONSHIP (SAR) STUDY , 2011 .

[14]  Kamil Kuca,et al.  Preparation, in vitro screening and molecular modelling of symmetrical bis-quinolinium cholinesterase inhibitors--implications for early myasthenia gravis treatment. , 2011, Bioorganic & medicinal chemistry letters.

[15]  V. Dohnal,et al.  The preparation, in vitro screening and molecular docking of symmetrical bisquaternary cholinesterase inhibitors containing a but-(2E)-en-1,4-diyl connecting linkage , 2011, Journal of enzyme inhibition and medicinal chemistry.

[16]  V. Dohnal,et al.  Preparation and in vitro screening of symmetrical bis-isoquinolinium cholinesterase inhibitors bearing various connecting linkage--implications for early Myasthenia gravis treatment. , 2011, European journal of medicinal chemistry.

[17]  V. Dohnal,et al.  Preparation, in vitro screening and molecular modelling of symmetrical 4-tert-butylpyridinium cholinesterase inhibitors--analogues of SAD-128. , 2011, Bioorganic & medicinal chemistry letters.

[18]  V. Dohnal,et al.  Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkage-initial study for Myasthenia gravis implications. , 2010, Bioorganic & medicinal chemistry letters.

[19]  K. Kuča,et al.  Time-dependent changes in concentration of two clinically used acetylcholinesterase reactivators (HI-6 and obidoxime) in rat plasma determined by HPLC techniques after in vivo administration. , 2010, Analytical sciences : the international journal of the Japan Society for Analytical Chemistry.

[20]  V. Dohnal,et al.  Monoquaternary pyridinium salts with modified side chain-synthesis and evaluation on model of tabun- and paraoxon-inhibited acetylcholinesterase. , 2008, Bioorganic & medicinal chemistry.

[21]  K. Kuča,et al.  Design of a potent reactivator of tabun-inhibited acetylcholinesterase--synthesis and evaluation of (E)-1-(4-carbamoylpyridinium)-4-(4-hydroxyiminomethylpyridinium)-but-2-ene dibromide (K203). , 2007, Journal of medicinal chemistry.

[22]  Kamil Kuca,et al.  Treatment of organophosphate intoxication using cholinesterase reactivators: facts and fiction. , 2007, Mini reviews in medicinal chemistry.

[23]  K. Kuča,et al.  The Development of New Structural Analogues of Oximes for the Antidotal Treatment of Poisoning by Nerve Agents and the Comparison of Their Reactivating and Therapeutic Efficacy with Currently Available Oximes , 2007 .

[24]  K. Kuča,et al.  Prophylaxis Against Nerve Agent Intoxications , 2006 .

[25]  N. Viguié,et al.  Enzymes hydrolyzing organophosphates as potential catalytic scavengers against organophosphate poisoning , 1998, Journal of Physiology-Paris.

[26]  E. Albuquerque,et al.  The nonoxime bispyridinium compound SAD-128 alters the kinetic properties of the nicotinic acetylcholine receptor ion channel: a possible mechanism for antidotal effects. , 1989, The Journal of pharmacology and experimental therapeutics.

[27]  B. Lukey,et al.  A radioimmunoassay for pyridostigmine. , 1988, The Journal of pharmacology and experimental therapeutics.

[28]  Y. Kloog,et al.  Bisquaternary pyridinium oximes as allosteric inhibitors of rat brain muscarinic receptors. , 1985, Molecular pharmacology.

[29]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[30]  P. Lundy,et al.  Ganglion blocking properties of some bispyridinium soman antagonists. , 1979, European journal of pharmacology.

[31]  C. Broomfield,et al.  Effects of 1,1'-oxydimethylene bis-(4-tert-butylpyridinium chloride) (SAD-128) and decamethonium on reactivation of soman- and sarin-inhibited cholinesterase by oximes. , 1978, Biochemical pharmacology.